Senti Biosciences Holdings, Inc. Common Stock (SNTI) is a publicly traded Healthcare sector company. As of October 26, 2026, SNTI trades at $0.27 with a market cap of $5.87M and a P/E ratio of -0.12. SNTI moved -7.75% today. Year to date, SNTI is -84.08%; over the trailing twelve months it is -91.58%. Its 52-week range spans $0.17 to $5.10. Rallies surfaces SNTI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Senti Biosciences divests Midco and Opco to ST NewCo: Senti Biosciences transferred substantially all its existing business and pipeline to ST NewCo, retaining its Rett Syndrome and TIL programs. Consideration includes contingent value rights of up to $60 million tied to SENTI-202 milestones within seven years, and ST NewCo bought $2.5 million of common stock at closing.
| Metric | Value |
|---|---|
| Price | $0.27 |
| Market Cap | $5.87M |
| P/E Ratio | -0.12 |
| EPS | $-2.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.10 |
| 52-Week Low | $0.17 |
| Volume | 216.06K |
| Avg Volume | 0 |
| Revenue (TTM) | $22.00K |
| Net Income | $-61.44M |
| Gross Margin | 0.00% |
SNTI analyst coverage data. Average price target: $0.00.